BLife Therapeutics, a wholly-owned subsidiary of BetterLife Pharma Inc., is focused on the development of its patent pending Interferon formula, AP-003, for the treatment and prevention of severe COVID-19 disease. It’s parent, Better Life Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of Interferon therapeutics to meet unmet needs for patients worldwide with a pipeline of HPV-cervical dysplasia (AP-001) which has completed Phase 2 and AP-002, an oral gallium-based novel small molecule, US IND approved and has started Phase 1-2 in October 2019 in the US in cancer patients with advanced or recurrent solid tumours.
The group’s CEO Ahmad Doroudian expects the AP-003 Phase 2 trial to be completed in the next three-to-six months, and approved under emergency use authorization
Director Interviews
BetterLife Pharma reveals clinical trial updates on its treatment for mild-to-moderate coronavirus cases
Director Interviews
BetterLife surges on UK biotech trial results of interferon inhalation treatment for coronavirus
